Zobrazeno 1 - 10
of 17
pro vyhledávání: '"M Merchante Andreu"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M Merchante Andreu, Roberto P. Stock, Ricardo Ehrlich, Norbel Galanti, Rodolfo Paredes, Carolina Cabezón, Andrés Saralegui, Claudio Martínez
Publikováno v:
Journal of Cellular Biochemistry. 94:327-335
Echinococcus granulosus is the causative agent of hydatidosis, a major zoonoses that affects humans and herbivorous domestic animals. The disease is caused by the pressure exerted on viscera by hydatid cysts that are formed upon ingestion of E. granu
Autor:
E Fernández Alonso, M.A. Allende Bandrés, M Gimeno Gracia, T Salvador Gómez, I Puértolas Tena, M Merchante Andreu, MA Alcácera López, Y Lanza Salcines, B Bonaga Serrano
Publikováno v:
European Journal of Hospital Pharmacy. 23:A164.2-A164
Background The dispensation of enteral nutrition (EN) to institutionalised patients has recently being carried from the hospital pharmacy services corresponding to the health area. Hospital pharmacists can provide the development of pharmaceutical ca
Autor:
B Bonaga Serrano, MA Alcácera López, B Abad Bañuelos, I Puértolas Tena, B Amores Arriaga, M Merchante Andreu, T Salvador Gómez, E Guarc Prades, M Gimeno Gracia
Publikováno v:
European Journal of Hospital Pharmacy. 23:A241.2-A242
Background The emergency departments have operating characteristics that make them especially prone to the occurrence of medication errors (ME). These units represent one of the departments with the highest incidence of errors with serious outcomes.
Autor:
MP Pardo Jario, S Gamarra Calvo, MA Alcácera López, M Gimeno Gracia, E Fernández Alonso, I Puértolas Tena, M Merchante Andreu
Publikováno v:
European Journal of Hospital Pharmacy. 23:A75.1-A75
Background G-CSF biosimilars are an emerging class of biopharmaceutical agents that may become an interesting cost saving alternative to cope with the increasing burden of cancer. Frequently, these drugs are supported by limited clinical data at the
Autor:
M Merchante Andreu, MA Alcácera López, A Rodrigo Cáceres, MA Sagredo Samanes, I Puértolas Tena, A Callejo Pérez, S Trueba Insa, E Fernández Alonso, M Gimeno Gracia, V Compaired Turlán
Publikováno v:
European Journal of Hospital Pharmacy. 23:A244.1-A244
Background Cancer patients are characterised by a high frequency of attendance at the emergency services. Specialised care is required due to complications from chemotherapy treatments. It is important that patients are educated about what to expect
Autor:
E Guarc Prades, E Fernández Alonso, MJ Cumbraos Sánchez, MP Pardo Jario, M Merchante Andreu, M.A. Allende Bandrés, T Salvador Gómez, MA Alcácera López
Publikováno v:
European Journal of Hospital Pharmacy. 22:A190.1-A190
Background In June 2013, it was decided to start a protocol for the use of ranibizumab. Patients were grouped in order to fractionate vials in 0.5 ml syringes as a savings strategy under aseptic conditions. 3 doses of ranibizumab suitable for use are
Autor:
E Fernández Alonso, M.A. Allende Bandrés, M Merchante Andreu, MJ Cumbraos Sánchez, T Salvador Gómez, V Compaired Turlán, MA Alcácera López
Publikováno v:
European Journal of Hospital Pharmacy. 22:A60.1-A60
Background Metformin is one of the most commonly prescribed drugs for the treatment of type 2 DM. A potential complication of metformin is lactic acidosis (LA). This potential increased risk remains controversial. Purpose To evaluate the occurrence o
Autor:
M Gimeno Gracia, C Iñiguez Martinez, V Compaired Turlán, M Merchante Andreu, E Fernández Alonso, A Sanabria Sanchinel, MJ Cumbraos Sánchez
Publikováno v:
European Journal of Hospital Pharmacy. 22:A63.1-A63
Background Multiple sclerosis (MS) is a chronic and progressive inflammatory disease that attacks the central nervous system. Impaired walking is the most significant disability; about half the patients suffer from this pathology 20 years after diagn